NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Bonti, a privately-held, clinical-stage biotechnology company, today announced a corporate presentation by its CEO at the 2017 BIO International Convention in the Business Forum on Monday, June 19th at 4:15 PM (local time) in San Diego, CA. Mr. Hasan will highlight Bonti’s lead product candidate, EB-001, which is a novel botulinum neurotoxin with a unique target profile, characterized by fast onset of action and short duration of effect. The clinical safety and efficacy of EB-001 is being investigated in Phase 2 clinical trials.
EB-001’s target indications will address areas of unmet medical needs, where the molecule’s product profile is highly beneficial for opportunities in the treatment of musculoskeletal pain in both surgical and non-surgical therapeutic settings. A biologic that treats root cause and does so without the side effects of opioids, EB-001 is seen as a potential solution to the current opioid epidemic in the U.S. In addition, the unique profile of EB-001 could be used in many new and existing aesthetic settings and would be complementary to existing products, potentially expanding the market significantly.
Founded in 2015, Bonti has advanced rapidly from its early development stages to already having its lead product candidate, EB-001, in human clinical testing. Bonti’s co-founder and CEO will outline how the company established and attained aggressive milestones, describe its innovative development pipeline and comment on the firm’s future direction and goals. Based on 2016’s BIO attendance, over 16,000 biotechnology and pharmaceutical leaders are expected this year at the self-described Global Event for Biotechnology.
“We are elated for the opportunity to present Bonti and EB-001 to the global audience at this conference and to be considered among the most innovative technologies in biotech today,” conveyed Fauad Hasan, co-founder and CEO of Bonti. “It is a privilege to have been invited to speak at the 2017 BIO International Convention where all facets of biotechnology – from entrepreneurial companies developing a first product, like us, to Fortune 100 multinational enterprises – are represented. We’re also grateful for the honor of having been chosen as one of the finalist companies for the Buzz of BIO competition. We believe this reflects our aim to build an elite venture to quickly and successfully develop a novel neurotoxin with a target profile which offers unique clinical benefits for therapeutic and aesthetic indications.”
Bonti’s lead product candidate, EB-001, is an investigational botulinum neurotoxin serotype E (BoNT/E). EB-001 has a mechanism of action similar to the marketed BoNT/A products though it has a differentiated clinical profile. EB-001 has a fast onset of action (about 24 hours) and short duration of effect (about 4 weeks). Currently marketed BoNT/A products have an onset of action around 3-7 days and a duration of effect around 3-4 months. The unique target clinical profile of EB-001 is well suited for a vast range of aesthetic and therapeutic uses, including for the treatment of post-surgical and non-surgical musculoskeletal pain, with currently unmet needs.
Bonti, based in Newport Beach, California, is a rapidly emerging biotechnology company founded by world class neurotoxin experts with proven success at Allergan, one of the Fortune 500 fastest growing pharma companies. This team, with unsurpassed neurotoxin, aesthetic and pain expertise, is uniquely qualified to develop unprecedented treatment paradigms driven by a novel neurotoxin platform to become an innovative leader in both aesthetic and therapeutic markets. By turning the science of neurotoxins into beneficial patient and healthcare provider solutions, Bonti will improve lives by successfully addressing key unmet needs in markets with multi-billion dollar addressable opportunities.
For more information, please visit http://bonti.com.